Show source-provided references
2. Clough, J. (2009). The Cleveland Clinic Guide to Arthritis, Kaplan Publishing.
3. Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years
10.1093/rheumatology/kex172 ↗7. Osteoimmunology: Major and costimulatory pathway expression associated with chronic inflammatory induced bone loss
10.1155/2015/281287 ↗9. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption
10.1007/s001980070028 ↗13. Evidence for osteocyte regulation of bone homeostasis through RANKL expression
10.1038/nm.2452 ↗15. Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading
10.1016/j.bone.2004.05.024 ↗20. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis
10.1155/2013/125705 ↗25. Expression of osteoprotegerin, receptor activator of nf-κb ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing
10.1359/jbmr.2001.16.6.1004 ↗27. Chondrocytes-specific expression of osteoprotegerin modulates osteoclast formation in metaphyseal bone
10.1038/srep13667 ↗30. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: Expression of receptor activator nfκb, rank ligand and osteoprotegerin
10.1016/S0142-9612(03)00556-8 ↗33. Over-expression of receptor activator of nuclear factor-κb ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty
10.1016/j.biomaterials.2009.09.017 ↗35. Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts
10.1007/s11596-014-1265-5 ↗36. Functional human t-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection
10.1172/JCI10763 ↗38. Prostaglandin e2, interleukin 1α, and tumor necrosis factor-α increase human osteoclast formation and bone resorption in vitro
10.1210/endo.139.7.6085 ↗40. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption
10.1002/jor.1100170510 ↗42. Differential expression of rankl and osteoprotegerin in gingival crevicular fluid of patients with periodontitis
10.1177/154405910408300216 ↗46. Biological reactions to different dental implant surface treatments
48. Surface modification of biomedical and dental implants and the processes of inflammation, wound healing and bone formation
10.3390/ijms11010354 ↗50. Metal is not inert: Role of metal ions released by biocorrosion in aseptic loosening—Current concepts
10.1002/jbm.a.32625 ↗52. Titanium uptake, induction of RANK-L expression, and enhanced proliferation of human t-lymphocytes
10.1002/jor.21013 ↗58. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes a potential treatment for aseptic loosening of total joint components
10.2106/00004623-200107000-00012 ↗61. Use of bisphosphonates in orthopedic surgery
62. DeGroot, L.J., and Jameson, J.L. (2016). Bone development and remodeling. Endocrinology: Adult and Pediatric, Elsevier Health Sciences. [7th ed.].
65. Receptor activator of nuclear factor κb ligand and osteoprotegerin regulation of bone remodeling in health and disease
10.1210/er.2007-0014 ↗68. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials
10.1007/s10147-013-0561-6 ↗